A Molecular Signature of Gastric Metaplasia Arising in Response to Acute Parietal Cell Loss

Nozaki, Koji; Ogawa, Masako; Williams, Janice A.; LaFleur, Bonnie; Ng, Victor Wee Lin; Drapkin, Ronny; Mills, Jason C.; Konieczny, Stephen F.; Nomura, Sachiyo; Goldenring, James R.

doi:10.1053/j.gastro.2007.11.058

Cited by 149 publications

(199 citation statements)

References 22 publications

Supporting

Mentioning

185

Contrasting

Unclassified

Order By: Relevance

“…journals.viamedica.pl/ginekologia_polska cinomas when compared with non-small cell carcinomas such as squamous cell carcinomas, adenocarcinomas and large-cell lung cancers [4,[14][15][16]. In the gastrointestinal system, HE4 tissue overexpression was found in stomach [18], pancreatic, colorectal , and hepatocellular carcinomas [4,14,18,19]. In the urological tract, varying HE4 expression levels were showed in clear cell carcinomas, papillary renal cell carcinomas, and chromophobe carcinomas [4,12,[18][19][20].…”

Section: Discussionmentioning

confidence: 99%

“…In the gastrointestinal system, HE4 tissue overexpression was found in stomach [18], pancreatic, colorectal , and hepatocellular carcinomas [4,14,18,19]. In the urological tract, varying HE4 expression levels were showed in clear cell carcinomas, papillary renal cell carcinomas, and chromophobe carcinomas [4,12,[18][19][20]. Although HE4 expression has been extensively studied in several carcinomas, there are little or no data on the expression and significance of HE4 in the uterine cervical tumors.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Tissue expression of human epididymal secretory protein 4 may be useful in the differential diagnosis of uterine cervical tumors

Dınız

Karadeniz²,

Sayhan³

et al. 2017

Ginekol Pol

View full text Add to dashboard Cite

Objectives: Human Epididymal Secretory Protein 4 was firstly described as an epididymis-specific protein but more recently it has been demonstrated to be a putative serum tumor marker for different malignancies, especially ovarian epithelial cancers. The aim of this study is to investigate the association between tissue Human Epididymal Secretory Protein 4 expression and the clinicopathological features of uterine cervical tumors. Material and methods:This retrospective study was designed to evaluate the differences of tissue expressions of Human Epididymal Secretory Protein 4 protein in a spectrum of cervical neoplasms. One hundred and seven patients recently diagnosed as having cervical intraepithelial neoplasm or invasive squamous cell carcinoma, adenosquamous carcinoma and adenocarcinoma based on pathology databases.Results: Decreased or negative Human Epididymal Secretory Protein 4 expressions were determined in both normal cervical epithelia and in intraepithelial carcinomas, while increased HE4 expression was observed in invasive tumors. Conclusions:This study demonstrated that altered expression of Human Epididymal Secretory Protein 4 may involve in tumorigenesis in the uterine cervix. Our findings also suggested the presence of a correlation between Human Epididymal Secretory Protein 4 expression and the invasive potential of uterine tumors. Therefore it may be thought that the tissue expression of HE4 can be used to differentiate high grade intraepithelial tumors from carcinomas.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Tissue expression of human epididymal secretory protein 4 may be useful in the differential diagnosis of uterine cervical tumors

Dınız

Karadeniz²,

Sayhan³

et al. 2017

Ginekol Pol

View full text Add to dashboard Cite

show abstract

“…HE4 expression in digestive system and gastrointestinal cancers HE4 is undetectable in normal human stomach tissue with the use of immunohistochemistry method [26]. Nozaki and coworkers reported that HE4 level was elevated in all metaplasias of the stomach tissues in human and mice [84]. The same group further evaluated the expression of HE4 in metaplasias/preneoplastic precursors and adenocarcinomas of the stomach, esophagus, and pancreas.…”

Section: Inflammatory Diseasementioning

confidence: 99%

Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies

Duan

et al. 2016

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

“…For example, there are distinct types of IMs, not all carrying definitive preneoplastic potential, and some authors have argued that IM in general is a paraneoplastic condition because the earliest gastric carcinomas arise from gas-tric, not intestinalized, glands. [5][6][7][8][9][10] Also, traditional models do not take into account that atrophy of the corpus is almost always concomitant with pseudopyloric or spasmolytic polypeptide expressing metaplasia (SPEM; see below) 11,12 and neglects evidence that this type of metaplasia may have closer links to eventual development of dysplasia or carcinoma. 13 Recently, mouse models have argued for even more unexpected routes to the development of cancer, with a critical role of transdifferentiation of gastric epithelial cancer progenitors from migrating mesenchymal stem cells.…”

mentioning

confidence: 99%

The Transcription Factor MIST1 Is a Novel Human Gastric Chief Cell Marker Whose Expression Is Lost in Metaplasia, Dysplasia, and Carcinoma

Lennerz

Kim

Oates

et al. 2010

The American Journal of Pathology

Self Cite

105

144

View full text Add to dashboard Cite

The lack of reliable molecular markers for normal differentiated epithelial cells limits understanding of human gastric carcinogenesis. Recognized precursor lesions for gastric adenocarcinoma are intestinal metaplasia and spasmolytic polypeptide expressing metaplasia (SPEM), defined here by ectopic CDX2 and TFF2 expression, respectively. In mice, expression of the bHLH transcription factor MIST1, normally restricted to mature chief cells, is down-regulated as chief cells undergo experimentally induced metaplasia. Here, we show MIST1 expression is also a specific marker of human chief cells. The mainstays of therapy in gastric carcinoma are early recognition, resection, and neoadjuvant or adjuvant therapy. However, gastric cancer remains the second largest cause of cancer-related mortality worldwide, 1 which drastically illustrates our lack of understanding of the sequence and progression of preneoplastic conditions. The traditional linear progression model of cellular changes, such as (Helicobacter-mediated) inflammation, atrophy, intestinal metaplasia (IM), dysplasia, and carcinoma, 2-4 does not apply to all cases and does not allow incorporation of more recently recognized entities. For example, there are distinct types of IMs, not all carrying definitive preneoplastic potential, and some authors have argued that IM in general is a paraneoplastic condition because the earliest gastric carcinomas arise from gasSupported by

show abstract

A Molecular Signature of Gastric Metaplasia Arising in Response to Acute Parietal Cell Loss

Cited by 149 publications

References 22 publications

Tissue expression of human epididymal secretory protein 4 may be useful in the differential diagnosis of uterine cervical tumors

Tissue expression of human epididymal secretory protein 4 may be useful in the differential diagnosis of uterine cervical tumors

Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies

The Transcription Factor MIST1 Is a Novel Human Gastric Chief Cell Marker Whose Expression Is Lost in Metaplasia, Dysplasia, and Carcinoma

Contact Info

Product

Resources

About